Harte Hanks, Inc. , a leading global customer experience company focused on bringing companies closer to customers for over 100 years, today announced financial results for the third quarter ended ...

Shares of vaccine makers fell on reports that President-elect Donald Trump is expected to nominate Robert F. Kennedy Jr., a ...

SPR206 is an investigational, intravenously administered next-generation polymyxin that has shown antibiotic activity against MDR Gram-negative pathogens, including carbapenem-resistant ...

Analyst Roy Buchanan of JMP Securities reiterated a Buy rating on CureVac (CVAC – Research Report), retaining the price target of $16.00.